Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for APRE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -3.221M
March 31, 2026 -2.757M
December 31, 2025 -3.067M
September 30, 2025 -3.267M
June 30, 2025 -3.478M
March 31, 2025 -3.631M
December 31, 2024 -3.171M
September 30, 2024 -2.627M
June 30, 2024 -3.546M
March 31, 2024 -3.944M
December 31, 2023 -3.872M
September 30, 2023 -2.173M
June 30, 2023 -3.187M
March 31, 2023 -2.979M
Date Value
December 31, 2022 -4.038M
September 30, 2022 -5.535M
June 30, 2022 -8.532M
March 31, 2022 -5.495M
December 31, 2021 -9.542M
September 30, 2021 -7.700M
June 30, 2021 -7.741M
March 31, 2021 -11.52M
December 31, 2020 -14.36M
September 30, 2020 -13.16M
June 30, 2020 -9.64M
March 31, 2020 -7.554M
December 31, 2019 -10.44M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Zymeworks, Inc. -31.59M
Rhythm Pharmaceuticals, Inc. -9.152M
Onconetix, Inc. -1.918M
ACADIA Pharmaceuticals, Inc. 95.69M
Alnylam Pharmaceuticals, Inc. 292.04M